Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1631 1633 1634
This examiner grants 55% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17617490 | ENGINEERED HUMAN-ENDOGENOUS VIRUS-LIKE PARTICLES AND METHODS OF USE THEREOF FOR DELIVERY TO CELLS | Final Rejection | President and Fellows of Harvard College |
| 19342217 | CAPSID POLYPEPTIDES AND METHODS OF USE THEREOF | Non-Final OA | DYNO THERAPEUTICS, INC. |
| 18011799 | METHODS AND COMPOSITIONS RELATED TO CATALYTIC ACTIVATION OF HUMAN ARGONAUTE-3 | Final Rejection | OHIO STATE INNOVATION FOUNDATION |
| 18019423 | Molecular Targets for Modulation of Dissociative and Associative States | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17820525 | INHIBITORY CHIMERIC RECEPTOR ARCHITECTURES | Final Rejection | TRUSTEES OF BOSTON UNIVERSITY |
| 16510259 | AAV-MEDIATED GENE THERAPY FOR NPHP5 LCA-CILIOPATHY | Non-Final OA | University of Florida Research Foundation, Inc. |
| 19042220 | PRODUCTION OF VIRUS VECTOR PLASMID IN BACILLUS SUBTILIS | Non-Final OA | Synplogen Co., Ltd. |
| 18251737 | PRODUCTION OF VIRUS VECTOR PLASMID IN BACILLUS SUBTILIS | Non-Final OA | Synplogen Co., Ltd. |
| 16969098 | CHIMERIC ANTIGEN RECEPTORS TARGETING THE TUMOR MICROENVIRONMENT | Final Rejection | The General Hospital Corporation |
| 18873212 | VACCINE COMPRISING NATURAL KILLER CELLS LOADED WITH LIGANDS OF NATURAL KILLER T CELLS AND CANCER ANTIGENS | Non-Final OA | CELLID CO., LTD. |
| 18031486 | Engineered Cells for Increased Collagen Production | Final Rejection | Northeastern University |
| 17806581 | RECOMBINANT VIRUS REPLICON SYSTEMS AND USES THEREOF | Final Rejection | Janssen Pharmaceuticals, Inc. |
| 17768778 | NON-CODING RNA PROTECTING AGAINST HEART FAILURE | Final Rejection | MEDIZINISCHE HOCHSCHULE HANNOVER |
| 18360217 | RAPID HIGH THROUGHPUT SCREENING SYSTEM TO ASSESS POTENTIAL TREATMENTS FOR SPORADIC ALZHEIMER’S DISEASE | Non-Final OA | Trustees of Tufts College |
| 18567499 | LENTIVIRAL VECTOR | Non-Final OA | TOUCHLIGHT IP LIMITED |
| 18561931 | NOVEL METHOD FOR ISOLATING AND CULTURING DERMAL PAPILLA CELLS | Non-Final OA | EPI BIOTECH CO., LTD. |
| 17841029 | POLYNUCLEOTIDE EDITORS AND METHODS OF USING THE SAME | Non-Final OA | PRIME MEDICINE, INC. |
| 17353587 | METHODS FOR CONTROLLED ACTIVATION OR ELIMINATION OF THERAPEUTIC CELLS | Final Rejection | Board of Regents of The University of Texas System |
| 17610111 | OPTIMIZED PHENYLANANINE HYDROXYLASE EXPRESSION | Final Rejection | American Gene Technologies International Inc. |
| 16965895 | USE OF LENTIVIRAL VECTORS EXPRESSING FACTOR VIII | Final Rejection | BIOVERATIV THERAPEUTICS INC. |
| 17771421 | ORNITHINE TRANSCARBAMYLASE (OTC) CONSTRUCTS AND METHODS OF USING THE SAME | Final Rejection | Genevant Sciences GmbH |
| 17479577 | RECOMBINANT ADENO-ASSOCIATED VIRUS VECTORS | Final Rejection | Ginkgo Bioworks, Inc. |
| 17927460 | COMPOSITIONS AND METHODS FOR AUGMENTING CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPIES | Final Rejection | Tiziana Life Sciences PLC |
| 17611460 | GENE THERAPY WITH THE GENES HOKD AND LDRB FOR CANCER TREATMENTS | Final Rejection | SERVICIO ANDALUZ DE SALUD |
| 17952565 | CELL-BASED VEHICLES FOR POTENTIATION OF VIRAL THERAPY | Non-Final OA | CALIDI BIOTHERAPEUTICS (NEVADA), INC. |
| 17843912 | METHODS OF OBTAINING TUMOR-SPECIFIC T CELL RECEPTORS | Non-Final OA | HRYZ Biotech Co. |
| 17843917 | METHODS OF OBTAINING TUMOR-SPECIFIC T CELL RECEPTORS | Non-Final OA | HRYZ Biotech Co. |
| 17752966 | Compositions and Methods for Treating Cancer with DuoCARs | Final Rejection | Lentigen Technology, Inc. |
| 17765368 | COMPOSITIONS AND METHODS FOR OCULAR THERAPY | Non-Final OA | The Provost, Fellows, Foundation Scholars, and the other members of Board, of the College of the |
| 17241857 | AMPLICON EXPRESSION VECTOR VACCINES | Non-Final OA | Evvivax S.R.L. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy